NRNP 6630 Midterm Exam (Version-1,Latest-2022/2023, 100 Q & A) / NRNP6630 Midterm Exam / NRNP 6630 Week 6 Midterm Exam / NRNP6630 Week 6 Midterm Exam: Walden University | 100% Verified

•
NRNP 6630 Midterm Exam



1 out of 1
I I I




I points
Question 1
I I




When an unstable patient asks why it is necessary to add medications to his
I I I I I I I I I I I I I


current regimen, the PMHNP’s best response would be:
I I I I I I I I




Selected C. I


I
Answer: “Many psychiatric illnesses involve several dys-functioning neurotransmitter systems in
I I I I I I I I




the Ibrain. IOften, Ia Isingle Imedication Imay Ionly Ieffect Ione Ior Itwo Iof Ithe Idys-functioning
I

systems. IThe Iaddition Iof Ianother Imedication Ican Iwork Iwith Ithe Icurrent Imedication Iin
I


symptoms.”
stabilizing Imultiple Ineurotransmitter Isystems Iand Ihelp Ito Ialleviate Iyour I
I




• Question 2 I


0 out of 1 points
I I I I



The PMHNP is meeting with a new mother who would like to begin taking
I I I I I I I I I I I I I


medication again to treat her bipolar depression; she is breastfeeding her 2-
I I I I I I I I I I I I


month old daughter. The PMHNP recognizes that which of the following
I I II I I I I I I I

medications is contraindicated for this patient? I I I I I I




Selected Answer: C.I I


Lithium (Lithobid) I




• Question 3 I


1 out of 1 points
I I I I



Mr. Gordon is a middle-aged client who was started on antidepressant
I I I I I I I I I I

, I monotherapy for depression. After beginning this medication, the PMHNP
I I II I I I I I


I noticed that this client seemed to swing into a hypomanic episode. What can
I I I I I I I I I I I I


the PMHNP infer from this behavior change?
I I I I I I I


Selected Answer: A. I I


This client may have Bipolar III disorder
I I I I I I




• Question 4 I


1 out of 1 points
I I I I



A patient presents with frequent episodes of mania. Which statement describes
I I I I I I I I I I




I an appropriate treatment approach for this patient?
I I I I I I




Selected Answer: B. I I


“The patient could benefit from an anticonvulsant.”
I I I I I I II




• Question 5 I


1 out of 1 points
I I I I




The student inquires about antipsychotic medications. Which response by the
I I I I I I I I I


PMHNP describes the factors that contribute to reduced risk of extrapyramidal
I I I I I I I I I I I


symptoms (EPS) for patients who take antipsychotics?
I I I I I I I




Selected B. I


I Answer: Those that are potent D2 antagonists with 5HT2A antagonism
I I I I I I I I


properties
I




• Question 6 I


1 out of 1 points I I I I


After ordering flumazenil (Rumazicon) the PMHNP cautions the staff to monitor for
I I I I I I I I I I I


Iwhich possible effect? I I


Selected Answer: D. I I


All of the above I I I

, A




• Question 7 I


1 out of 1 points
I I I I



The PMHNP is caring for a patient who is taking antipsychotics heard the
I I I I I I I I I I I I


psychiatrist tell the patient that the patient would be placed on a different
I I I I I I I I I I I I I


antipsychotic agent called an atypical antipsychotic. What neurotransmitters
I I I I I I I I


will this new medication work on?
I I I I I I


Selected Answer: A. I I


dopamine and serotonin I I




• Question 8 I


1 out of 1 points
I I I I



While genes have potential to modify behavior, behavior can also modify genes.
I I I I I I I I I I I



How do genes impact this process?
I I I I I I




Selected Answer: B. I I


Changes made to proteins lead to changes in behavior.
I I I I I I I I




• Question 9 I


1 out of 1 points
I I I I



Mrs. Schwartzman is a 52-year-old client with schizophrenia and no
I I I I I I I I I


established history of depression. When meeting with the PMHNP, she
I I I I I I I I I I


presents with apathy and withdrawn social behavior, and she reports a loss
of
I I I I I I I I I I I I I



I joy from enjoyable activities since starting her new medication. What does the
I I I I I I I I I I I


I PMHNP infer from this encounter with the client?
I I I I I I I


Selected C. I


IAnswer: The new medication is blocking D2 receptors in the mesolimbic
I I I I I I I I I


Isystem